Improving Treatment Approaches for Rectal Cancer
Abstract
The cure rate for nonmetastatic rectal cancer has been improving for decades. Treatment for stage II and III rectal adenocarcinomas now routinely includes surgery, radiation therapy, and chemotherapy. The results of recent phase 3 trials have led to an increase in the intensity of treatment to include multiagent chemotherapy in addition to radiation therapy before proctectomy is performed; such treatment has resulted in a 3-year disease-free survival rate as high as 77%.1,2 Unfortunately, this treatment approach is grueling and can cause substantial long-term sequelae, including neuropathy, infertility, and bowel and sexual dysfunction. However, this more aggressive preoperative treatment also opens . . .
Continue reading this article
Select an option below:
Create your account to get 2 free subscriber-only articles each month.
Get Free Access Now Subscribe For Full AccessNotes
This editorial was published on June 5, 2022, at NEJM.org.
Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.
Supplementary Material
Disclosure Forms (nejme2204282_disclosures.pdf)
- Download
- 94.41 KB
Information & Authors
Information
Published In
Copyright
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
History
Published online: June 5, 2022
Published in issue: June 23, 2022
Topics
Authors
Affiliations
From the Division of Oncology and the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
Metrics & Citations
Metrics
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy, Molecules, 28, 23, (7750), (2023).https://doi.org/10.3390/molecules28237750
- The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer, Cancers, 15, 14, (3688), (2023).https://doi.org/10.3390/cancers15143688
- Current Controversies in the Management of Locally Advanced Colon Cancer, The American Surgeon™, 89, 8, (3361-3371), (2023).https://doi.org/10.1177/00031348231175490
- Beeindruckende Effektivität der primären PD-1-Hemmung, Gastro-News, 10, 3, (20-23), (2023).https://doi.org/10.1007/s15036-023-3232-0
- Beeindruckende Effektivität der primären PD-1-Hemmung, InFo Hämatologie + Onkologie, 26, 1-2, (22-23), (2023).https://doi.org/10.1007/s15004-022-9814-8
- The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer, Handbook of Oncobiology: From Basic to Clinical Sciences, (1-43), (2023).https://doi.org/10.1007/978-981-99-2196-6_62-1
- Signaling pathways and therapeutic interventions in gastric cancer, Signal Transduction and Targeted Therapy, 7, 1, (2022).https://doi.org/10.1038/s41392-022-01190-w
- Epigenetics and Anticipatory Processes: From the Empirical to Foundational Aspects, Epigenetics and Anticipation, (201-234), (2022).https://doi.org/10.1007/978-3-031-17678-4_12
Loading...